Oxford Immunotec Global PLC (NASDAQ:OXFD) Shares Sold by Redmile Group LLC
Redmile Group LLC trimmed its position in shares of Oxford Immunotec Global PLC (NASDAQ:OXFD) by 10.1% in the first quarter, HoldingsChannel.com reports. The fund owned 2,001,467 shares of the company’s stock after selling 226,040 shares during the period. Redmile Group LLC owned 0.08% of Oxford Immunotec Global worth $34,485,000 at the end of the most recent quarter.
A number of other institutional investors have also recently made changes to their positions in the stock. FIL Ltd acquired a new stake in Oxford Immunotec Global in the 1st quarter valued at about $5,586,000. Martingale Asset Management L P acquired a new stake in Oxford Immunotec Global in the 4th quarter valued at about $1,499,000. Bellevue Group AG raised its position in Oxford Immunotec Global by 38.2% in the 4th quarter. Bellevue Group AG now owns 306,606 shares of the company’s stock valued at $3,918,000 after purchasing an additional 84,769 shares in the last quarter. EAM Global Investors LLC acquired a new stake in Oxford Immunotec Global in the 1st quarter valued at about $1,330,000. Finally, Marshall Wace LLP acquired a new stake in Oxford Immunotec Global in the 1st quarter valued at about $1,185,000. Institutional investors own 91.57% of the company’s stock.
OXFD stock opened at $14.07 on Monday. The company has a current ratio of 12.60, a quick ratio of 12.03 and a debt-to-equity ratio of 0.04. The stock has a market capitalization of $374.59 million, a price-to-earnings ratio of 27.59 and a beta of 0.42. Oxford Immunotec Global PLC has a 1 year low of $11.66 and a 1 year high of $19.19.
In other news, Director Richard A. Sandberg sold 3,000 shares of the firm’s stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $16.05, for a total transaction of $48,150.00. Following the sale, the director now owns 3,000 shares of the company’s stock, valued at approximately $48,150. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Peter Wrighton-Smith sold 10,600 shares of the firm’s stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $16.68, for a total value of $176,808.00. Following the sale, the chief executive officer now directly owns 445,138 shares in the company, valued at approximately $7,424,901.84. The disclosure for this sale can be found here. 6.61% of the stock is currently owned by company insiders.
A number of equities research analysts have issued reports on the company. Zacks Investment Research lowered Oxford Immunotec Global from a “buy” rating to a “hold” rating in a research report on Wednesday, April 17th. BidaskClub raised Oxford Immunotec Global from a “sell” rating to a “hold” rating in a research report on Tuesday, May 7th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and two have given a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $18.00.
Oxford Immunotec Global Profile
Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for immunology and infectious diseases in the United States. It develops its products using its T-SPOT technology platform, which enables the measurement of responses of specific immune cells to inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions.
Featured Story: Liquidity
Want to see what other hedge funds are holding OXFD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Oxford Immunotec Global PLC (NASDAQ:OXFD).
Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.